Loading stock data…
$12.64+0.44 (+3.61%)
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
4D Molecular Therapeutics, Inc. in the Healthcare sector is trading at $12.57 with a market capitalization of $841M. Wall Street consensus targets $28.09 (11 analysts), implying a +123.5% move over the next 12 months. The stock is currently 26% below its 52-week high of $16.93, remaining 18.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.78M↑ | $3.05M↓ | $85.09M↑ | $90,000↑ | $15,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$77.03M↓ | -$73.62M↓ | $14.71M↑ | -$61.19M↓ | -$59.46M |
| Net Income | -$72.94M↓ | -$68.76M↓ | $19.40M↑ | -$56.88M↓ | -$54.66M |
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United...